Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

Cited In for PubMed (Select 20177359)

1.

Evaluating the Impact of Test-and-Treat on the HIV Epidemic among MSM in China Using a Mathematical Model.

Luo S, Han L, Lu H, Dou Z, Tao Q, Khoshnood K, Wu Z, Xu J.

PLoS One. 2015 Jun 3;10(6):e0126893. doi: 10.1371/journal.pone.0126893. eCollection 2015.

2.

HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.

Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, Bock P, Griffith S, Moore A, Watson-Jones D, Fraser C, Vermund SH, Fidler S; HPTN 071 (PopART) Study Team.

Trials. 2014 Feb 13;15:57. doi: 10.1186/1745-6215-15-57.

3.
4.

Massive benefits of antiretroviral therapy in Africa.

Vermund SH.

J Infect Dis. 2014 Feb 15;209(4):483-5. doi: 10.1093/infdis/jit586. Epub 2013 Dec 3. No abstract available.

5.

Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study.

Hontelez JA, Lurie MN, Bärnighausen T, Bakker R, Baltussen R, Tanser F, Hallett TB, Newell ML, de Vlas SJ.

PLoS Med. 2013 Oct;10(10):e1001534. doi: 10.1371/journal.pmed.1001534. Epub 2013 Oct 22.

6.

Balancing efficiency, equity and feasibility of HIV treatment in South Africa - development of programmatic guidance.

Baltussen R, Mikkelsen E, Tromp N, Hurtig A, Byskov J, Olsen O, Bærøe K, Hontelez JA, Singh J, Norheim OF.

Cost Eff Resour Alloc. 2013 Oct 9;11(1):26. doi: 10.1186/1478-7547-11-26.

7.

Prospects of elimination of HIV with test-and-treat strategy.

Kretzschmar ME, Schim van der Loeff MF, Birrell PJ, De Angelis D, Coutinho RA.

Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15538-43. doi: 10.1073/pnas.1301801110. Epub 2013 Sep 5.

8.

Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review.

Kulkarni SP, Shah KR, Sarma KV, Mahajan AP.

Am J Public Health. 2013 Jun;103(6):e14-23. doi: 10.2105/AJPH.2013.301273. Epub 2013 Apr 18. Review.

9.

Adherence to antiretroviral therapy and clinical outcomes among young adults reporting high-risk sexual behavior, including men who have sex with men, in coastal Kenya.

Graham SM, Mugo P, Gichuru E, Thiong'o A, Macharia M, Okuku HS, van der Elst E, Price MA, Muraguri N, Sanders EJ.

AIDS Behav. 2013 May;17(4):1255-65. doi: 10.1007/s10461-013-0445-9.

10.

Combination prevention: new hope for stopping the epidemic.

Vermund SH, Hayes RJ.

Curr HIV/AIDS Rep. 2013 Jun;10(2):169-86. doi: 10.1007/s11904-013-0155-y. Review.

11.

Economics of antiretroviral treatment vs. circumcision for HIV prevention.

Bärnighausen T, Bloom DE, Humair S.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21271-6. doi: 10.1073/pnas.1209017110. Epub 2012 Dec 6.

12.

Sexually transmitted infection testing and self-reported diagnoses among a community sample of men who have sex with men, in Scotland.

McDaid LM, Li J, Knussen C, Flowers P.

Sex Transm Infect. 2013 May;89(3):223-30. doi: 10.1136/sextrans-2012-050605. Epub 2012 Oct 5.

13.

Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages.

Eaton LA, Huedo-Medina TB, Kalichman SC, Pellowski JA, Sagherian MJ, Warren M, Popat AR, Johnson BT.

Am J Public Health. 2012 Nov;102(11):e34-44. doi: 10.2105/AJPH.2012.300968. Epub 2012 Sep 20.

14.

Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs.

Wagner BG, Blower S.

PLoS One. 2012;7(9):e41212. doi: 10.1371/journal.pone.0041212. Epub 2012 Sep 5.

15.

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators.

PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31.

16.

HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.

Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB.

PLoS Med. 2012;9(7):e1001245. doi: 10.1371/journal.pmed.1001245. Epub 2012 Jul 10.

17.

HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation.

Delva W, Wilson DP, Abu-Raddad L, Gorgens M, Wilson D, Hallett TB, Welte A.

PLoS Med. 2012;9(7):e1001239. doi: 10.1371/journal.pmed.1001239. Epub 2012 Jul 10.

18.

Universal testing and treatment as an HIV prevention strategy: research questions and methods.

Hayes R, Sabapathy K, Fidler S.

Curr HIV Res. 2011 Sep;9(6):429-45. Review.

19.

Treatment as prevention: preparing the way.

Williams B, Wood R, Dukay V, Delva W, Ginsburg D, Hargrove J, Stander M, Sheneberger R, Montaner J, Welte A.

J Int AIDS Soc. 2011 Jul 6;14 Suppl 1:S6. doi: 10.1186/1758-2652-14-S1-S6.

20.

The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period.

Krentz HB, Gill MJ.

AIDS Res Treat. 2012;2012:757135. doi: 10.1155/2012/757135. Epub 2011 Aug 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk